Journal
ECANCERMEDICALSCIENCE
Volume 9, Issue -, Pages -Publisher
CANCER INTELLIGENCE LTD
DOI: 10.3332/ecancer.2015.523
Keywords
breast neoplasm; trastuzumab; neoadjuvant therapy; adjuvant therapy; antibodies; monoclonal; humanised
Categories
Ask authors/readers for more resources
The evolving field of HER2-targeted therapy has significantly improved the outcome of women diagnosed with HER2-positive invasive breast cancer. In this review, we sought to summarise the efficacy of trastuzumab-based regimens in the adjuvant and neoadjuvant setting with a special emphasis on relevant clinical questions: treatment duration, sequence of trastuzumab administration, toxicity, the role of anthracycline-based regimens, and optimal management of small HER2+ tumours. Controversial topics are discussed taking into consideration the development of modern anti-HER2 agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available